Free tool
FAERS Monitor: Yutiq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210331 or its brand name (Yutiq, Fluocinolone Acetonide). Reports on generic versions are filed under their own applications.
Reports
2,444
Serious
757
31% of reports
Hospitalization
274
Death reported
42
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use519
- product dose omission issue199
- drug ineffective187
- pruritus166
- rash143
- no adverse event130
- diarrhoea115
- psoriasis95
- headache90
- fatigue89
- pain85
- nausea81
- dermatitis atopic80
- product use in unapproved indication73
- dry skin71
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 14 |
| 2006 | 7 |
| 2007 | 11 |
| 2008 | 9 |
| 2009 | 15 |
| 2010 | 17 |
| 2011 | 28 |
| 2012 | 32 |
| 2013 | 17 |
| 2014 | 26 |
| 2015 | 53 |
| 2016 | 75 |
| 2017 | 66 |
| 2018 | 73 |
| 2019 | 115 |
| 2020 | 163 |
| 2021 | 174 |
| 2022 | 286 |
| 2023 | 190 |
| 2024 | 585 |
| 2025 | 295 |
| 2026 | 185 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,715 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dermatitis atopicSignal | 80 | 13.1 | 10.5 | 881 |
| psoriasisSignal | 95 | 6.3 | 5.1 | 417 |
| no adverse eventSignal | 130 | 6.2 | 5.2 | 564 |
| product dose omission issueSignal | 199 | 5.8 | 5.1 | 802 |
| off label useSignal | 519 | 5.1 | 4.7 | 1,781 |
| dry skinSignal | 71 | 4.6 | 3.6 | 196 |
| pruritusSignal | 166 | 3.7 | 3.2 | 333 |
| rashSignal | 143 | 2.8 | 2.4 | 170 |
| product use in unapproved indicationSignal | 73 | 2.5 | 2.0 | 67 |
| diarrhoea | 115 | 1.5 | 1.3 | 21 |
| headache | 90 | 1.2 | 1.0 | 4 |
| drug ineffective | 187 | 1.2 | 1.1 | 8 |
| pain | 85 | 1.2 | 1.0 | 2 |
| fatigue | 89 | 1.0 | 0.8 | 0 |
| nausea | 81 | 0.9 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.